Novel library synthesis of 3,4-disubstituted pyridin-2(1H)-ones via cleavage of pyridine-2-oxy-7-azabenzotriazole ethers under ionic hydrogenation conditions at room temperature.

In our hands, efficient access to the 4-amino-3-carboxamide disubstituted pyridine-2(1H)-one kinase hinge-binder motif proved to be more challenging than anticipated requiring a significant investment in route scouting and optimization. This full paper focuses on the synthesis issues that we encountered during our route exploration and the original solutions we found that helped us to identify two optimized library-style processes to prepare our large kinase inhibitor library.

New Caspase-1 inhibitor by scaffold hopping into bio-inspired 3D-fragment space.

Virtual fragmentation of a library of 12,000 compounds inspired by natural products led to a dataset of 153,000 fragments that was used as a source to identify effective P2-P3 scaffold replacement solutions for peptidic Caspase-1 inhibitors. Our strategy led to the identification of an original 2-azabicyclo-octane scaffold (2-ABO) that was further elaborated into the potent Caspase-1 inhibitor CD10847 (IC50 = 17 nM). The crystal structure of Caspase-1 in complex with CD10847 was obtained, and its binding mode was shown to be similar to the one predicted by docking and in good agreement with other known inhibitors.

Rational Drug Design of Topically Administered Caspase 1 Inhibitors for the Treatment of Inflammatory Acne.

The use of an interleukin ß antibody is currently being investigated in the clinic for the treatment of acne, a dermatological disorder affecting 650M persons globally. Inhibiting the protease responsible for the cleavage of inactive pro-IL1ß into active IL-1ß, caspase-1, could be an alternative small molecule approach. This report describes the discovery of uracil 20, a potent (38 nM in THP1 cells assay) caspase-1 inhibitor for the topical treatment of inflammatory acne. The uracil series was designed according to a published caspase-1 pharmacophore model involving a reactive warhead in P1 for covalent reversible inhibition and an aryl moiety in P4 for selectivity against the apoptotic caspases. Reversibility was assessed in an enzymatic dilution assay or by using different substrate concentrations. In addition to classical structure-activity-relationship exploration, topical administration challenges such as phototoxicity, organic and aqueous solubility, chemical stability in solution, and skin metabolic stability are discussed and successfully resolved.

Interplay between lead carboxylate and Ti or Zr isopropoxides in solution routes to perovskites: synthesis, molecular structures and reactivity of single source non-oxo Pb-Zr and Pb-Ti carboxylatoalkoxides supported by 2-ethylhexanoate ligands.

The reactions between Ti(O(i)Pr)(4) and Zr(2)(O(i)Pr)(8)(HO(i)Pr)(2), respectively, and lead 2-ethylhexanoate Pb(O(2)CC(7)H(15))(2) have been investigated at rt and by heating. The initial mixed-metal species, characterized by single-crystal X-Ray diffraction, were adducts namely Pb(4)Zr(4)(mu-O(2)CR')(8)(mu-OR)(6)(mu(3)-OR)(2)(OR)(8)(OHR)(2) and Pb(2)Ti(4)(mu-O(2)CR')(4)(mu-OR)(6)(mu(3)-OR)(2)(OR)(8) (R' = CHCH(Et)C(2)H(4)Me, R = (i)Pr) independently of the stoichiometry used. They are the first Pb-Ti and Pb-Zr non-oxo carboxylatoalkoxides reported. is also the first Pb-Zr species based on an alkoxide-carboxylate ligand set matching the PbZrO(3) stoichiometry. Both structures are centrosymmetric with six-coordinate transition metals, as required for the perovskite, and are based on triangular M(2)Pb cores (M = Zr, Ti). The lead centers display quite high coordination numbers, six and seven. The thermal and hydrolytic condensation reactions of and were investigated. Heat treatment of and elimination of the volatiles under vacuum afforded Pb(2)Ti(3)(mu(4)-O)(mu(3)-O)(mu-O(2)CC(7)H(15))(2)(mu-O(i)Pr)(6)(O(i)Pr)(4) resulting from extrusion of Ti(O(i)Pr)(4) and scrambling of carboxylate ligands. Characterization of the various compounds was achieved by elemental analysis, FT-IR, (1)H and (207)Pb NMR.